Ticker: LRMR

Larimar Therapeutics, Inc. (NASDAQ: LRMR) Quick read: the company is advancing its lead candidate nomlabofusp toward registrational milestones while burning cash faster as clinical and manufacturing activity ramps. FDA engagement is constructive (START pilot, RLSE dialogue) but a safety signal (a...

Company Overview: Larimar Therapeutics, Inc. (NASDAQ: LRMR) is a clinical-stage biotechnology company focusing on treating patients with rare diseases. Its lead product candidate, nomlabofusp, aims to deliver human frataxin to mitochondria, addressing Friedreich’s ataxia, a rare and progressive g...